Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Xanthigen and Its Impact on Weight and Metabolic Health

NCT07519980 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2026-02-02
Last updated
2026-05-07

Condition(s) studied

Obesity & Overweight

Investigational drug(s) / intervention(s)

Experimental group: Xanthigen®Control product

Experimental group: Xanthigen®: They will take one capsule per day.

Control product: They will take one capsule per day.

Study summary

Randomized, controlled, triple-blind clinical trial with three parallel arms based on the product consumed (low-dose experimental product, high-dose experimental product, and placebo product) and conducted at a single center to measure the efficacy of a product (Xanthigen®) on overweight or obesity during 16 weeks of consumption.

Eligibility

Sex
ALL
Min age
20 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria: * The subject is able and willing to follow the study protocol procedures to sign the informed consent form prior to the evaluations. * Participants must be between 20 and 50 years of age at the time of consent. * The subject is in good physical and mental health as determined by medical history, physical examination, electrocardiogram, vital signs, biochemistry, and hematology results. * Participants must have a BMI between 27 and 29.9 kg/cm2. * Desire to lose weight. Exclusion Criteria: * Relevant medical history or presence of any medical condition that could interfere with this study, such as a previous diagnosis of diabetes, hypertension, hyperlipidemia, cardiovascular disease, thyroid disease, asthma, arthritis, or inflammatory conditions. * Fasting blood sugar levels greater than 125 mg/dL and/or total cholesterol levels greater than or equal to 240 mg/dL. * Blood pressure levels below 90/140 mm Hg (diastolic/systolic). * Chronic intake of medications/dietary supplements with an impact on body weight or body composition or lipid-modifying products (e.g., protein shakes, statins, omega-3 fatty acids, etc.) 2 months prior to selection or during the study. * Known allergy/sensitivity to any of the components of the investigational product. * Change in hormonal contraception or any use of hormone replacement therapy (HRT) during or at least 3 months prior to the study (if female). * Women of childbearing age who are pregnant or intend to become pregnant during the study period. * Use of any dietary supplements (except mineral supplements, e.g., Ca, Mg). * Participation in any weight loss intervention or recent change in body weight \> 4.5 kg during the last 9 months. * History and/or presence of eating disorders such as bulimia, anorexia nervosa, or binge eating, as determined by the investigator. * Consumption of any dietary supplements (except mineral supplements, e.g., Ca, Mg). * Participation in any weight loss program or recent change in body weight \> 4.5 kg during the last 9 months. * History and/or presence of eating disorders such as bulimia, anorexia nervosa, binge eating, as determined by the investigator. * Individuals who currently participate in aerobic exercise more than 4 times per week, or more than 2.5 hours per week. * Vegan lifestyle. * Current smoker or user of nicotine products or cessation of smoking within 1 year of the screening date. * Gastrointestinal diseases/conditions (colitis ulcers, Crohn's disease, peptic ulcers, celiac disease).

Primary outcome measure(s)

  • Weight — It will be measured at the beginning and at least once during the 4 months of consumption.
    Evaluate the effects of chronic supplementation with two doses (600 and 300mg) of Xanthigen® on weight loss. Body weight refers to the measurement of a person's total mass in kilograms. It is a basic variable that indicates the amount of mass a person has in their body. It will be assessed using the TANITA.

Trial sites (1)

FacilityCityRegionStatus
UCAM HiTech, Sport & Health Innovation Hub Murcia Murcia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07519980 on ClinicalTrials.gov ↗ ← All trials in Spain